Allergy Therapeutics starts dosing peanut allergy vaccine candidate
27th Mar 2023 15:16
(Sharecast News) - Allergy Therapeutics, a UK-based biotechnology company specialising in allergy vaccines, announced the start of the first application of its 'VLP Peanut' vaccine candidate in peanut-allergic patients on Monday.
Read moreAllergy Therapeutics confident in funding as results remain late
20th Jan 2023 12:33
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics said in an update on Friday that it expects first-half revenue of £39.9m, making for a decrease of 18% year-on-year.
Read moreAllergy Therapeutics pauses production at Freeman facility
4th Oct 2022 14:10
(Sharecast News) - Biotechnology company Allergy Therapeutics has "proactively paused" production at the Freeman facility, part of its Worthing manufacturing site, to accelerate ongoing site improvements, it announced on Tuesday.
Read moreAllegy Therapeutics trades 'robustly' in tough year
15th Jul 2022 11:58
(Sharecast News) - Allergy Therapeutics updated the market on the financial year just ended on Friday, with the phase one 'Peanut PROTECT' trial, incorporating "ground-breaking" VLP technology, proceeding as planned, with site initiation visits imminent.
Read moreAllergy Therapeutics reports positive results from field study
25th Oct 2021 10:45
(Sharecast News) - Biotechnology company Allergy Therapeutics announced positive top-line results from its exploratory field study 'G309' to evaluate the efficacy and safety of its short-course subcutaneous allergen-specific immunotherapy candidate 'Grass MATA MPL'.
Read moreAllergy Therapeutics upbeat on ex-vivo study of peanut allergy vaccine
3rd Aug 2021 13:43
(Sharecast News) - Pharmaceutical biotechnology company Allergy Therapeutics announced positive primary results from an ex-vivo biomarker study on Tuesday, evaluating its novel virus-like particle (VLP)-based peanut allergy vaccine candidate, VLP Peanut.
Read moreAllergy Therapeutics FY profits seen 'well ahead' of expectations
24th Jun 2021 08:07
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics said on Thursday that full-year operating profits were expected to be "well ahead" of market expectations thanks to "significantly lower" expenses.
Read moreAllergy Therapeutics completes treatment in G309 field study
6th May 2021 15:34
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics announced the completion of the treatment of all patients in its 'G309' exploratory field study to evaluate the efficacy and safety of Grass MATA MPL in subjects with seasonal allergic rhinitis or rhinoconjunctivitis, induced by grass pollen.
Read moreAllergy Therapeutics reports record pre-R&D operating profit
3rd Mar 2021 13:23
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics reported a 7% improvement in its revenue in actual terms in its interim results on Wednesday, and 5% growth at constant rate, to £54.0m.
Read moreAllergy Therapeutics begins peanut allergy vaccine study
5th Jan 2021 16:44
(Sharecast News) - Speciality allergy-focussed pharmaceutical company Allergy Therapeutics announced on Tuesday that an ex-vivo biomarker study of blood samples from peanut allergy patients had started at Imperial College London.
Read moreAllergy Therapeutics screens first patients in grass pollen study
26th Oct 2020 13:37
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics announced the screening of the first patient in its exploratory field study 'G309', to evaluate the efficacy and safety of 'Grass MATA MPL' in subjects with seasonal allergic rhinitis or rhinoconjunctivitis induced by grass pollen exposure.
Read moreAllergy Therapeutics signs new vaccine deal with Saliba and DeepVax
3rd Sep 2020 15:31
(Sharecast News) - Biotechnology company Allergy Therapeutics announced further investment in virus-like particle (VLP) technology for applications beyond the allergy immunotherapy field on Thursday.
Read moreAllergy Therapeutics revenues grow despite Covid-19 disruption
15th Jul 2020 09:03
(Sharecast News) - Biotechnology company Allergy Therapeutics reported a "strong" full-year performance on Wednesday despite challenges stemming from the Covid-19 pandemic.
Read moreAllergy Therapeutics pleased with invalidation of B301 trial data
9th Jul 2020 16:26
(Sharecast News) - Biotechnology company Allergy Therapeutics announced the outcome of scientific advice from the German Regulatory Authority, the Paul Ehrlich Institute (PEI), over invalidation of the primary endpoint data of the Birch MATA MPL pivotal phase 3 clinical trial, or 'B301', on Thursday.
Read moreAllergy Therapeutics on track to 'significantly' exceed FY expectations
24th Jun 2020 10:12
(Sharecast News) - Biotechnology company Allergy Therapeutics said on Wednesday that its 2020 trading performance was on track to exceed market expectations.
Read more